Literature DB >> 1688828

Identification of a T-cell epitope on the circumsporozoite protein of Plasmodium vivax.

F W George1, J L Law, K A Rich, W J Martin.   

Abstract

A series of overlapping peptides, representing sequences in the vicinity of region II on the Plasmodium vivax circumsporozoite protein, was synthesized. One of the peptides (PV-23), a 20-mer containing the 6 C-terminal amino acids of region II, was found to evoke an in vitro T-cell proliferative response in spleen cells from C3Hf (H-2km2) mice immunized with the peptide. These results demonstrate that PV-23 contains a T-cell epitope. To our knowledge, this is the first report of a T-cell epitope on the circumsporozoite protein of P. vivax.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688828      PMCID: PMC258498          DOI: 10.1128/iai.58.2.575-578.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.

Authors:  M F Good; D Pombo; I A Quakyi; E M Riley; R A Houghten; A Menon; D W Alling; J A Berzofsky; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules.

Authors:  F Sinigaglia; M Guttinger; J Kilgus; D M Doran; H Matile; H Etlinger; A Trzeciak; D Gillessen; J R Pink
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

3.  Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria.

Authors:  S L Hoffman; C N Oster; C Mason; J C Beier; J A Sherwood; W R Ballou; M Mugambi; J D Chulay
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

4.  Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

Authors:  W R Ballou; S L Hoffman; J A Sherwood; M R Hollingdale; F A Neva; W T Hockmeyer; D M Gordon; I Schneider; R A Wirtz; J F Young
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

5.  Does biased gene conversion influence polymorphism in the circumsporozoite protein-encoding gene of Plasmodium vivax?

Authors:  D E Arnot; J W Barnwell; M J Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope.

Authors:  D E Arnot; J W Barnwell; J P Tam; V Nussenzweig; R S Nussenzweig; V Enea
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

7.  Genetic restriction of the murine humoral response to a recombinant Plasmodium vivax circumsporozoite protein.

Authors:  E H Nardin; P J Barr; E Heimer; H M Etlinger
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

8.  Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein.

Authors:  M F Good; W L Maloy; M N Lunde; H Margalit; J L Cornette; G L Smith; B Moss; L H Miller; J A Berzofsky
Journal:  Science       Date:  1987-02-27       Impact factor: 47.728

9.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.

Authors:  D A Herrington; D F Clyde; G Losonsky; M Cortesia; J R Murphy; J Davis; S Baqar; A M Felix; E P Heimer; D Gillessen
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

10.  Molecular characterization of the C3HfB/HeN H-2Kkm2 mutation. Implications for the molecular basis of alloreactivity.

Authors:  J M Vogel; A C Davis; D M McKinney; M McMillan; W J Martin; R S Goodenow
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  1 in total

1.  Antibody response of humans to the circumsporozoite protein of Plasmodium vivax.

Authors:  E D Franke; C M Lucas; E San Roman
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.